| Expression pattern: |
DN |
| Associated gene: |
HO-1, AGO2, p-P65, p-P50, MMP3, MMP13, Aggrecan, Collagen II |
| Associated microRNA: |
miR-525-5p, miR-93-3p |
| Biological function: |
promotes chondrocyte proliferation; protects extracellular matrix (ECM) from degradation; suppresses oxidative stress; alleviates OA in vivo |
| Molecular mechanism: |
acts as an miRNA sponge for miR-525-5p to regulate HO-1, thereby influencing intracellular ROS and the HO-1/NF-kappaB pathway in chondrocytes |
| Biological pathway or process: |
NF-kappaB (inhibits); oxidative phosphorylation (unclear); inflammation (inhibits); proliferation (promotes); apoptosis (other); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Western Blot; IF (Immunofluorescence); IHC (Immunohistochemistry); Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; H&E Staining |
| Clinical significance: |
potential therapeutic target for the treatment of OA |
| Description: |
In osteoarthritis, circFNDC3B (hsa_circ_0001361) is down-regulated in human OA cartilage and IL-1beta-induced chondrocytes. It mainly localizes to the cytoplasm and acts as a ceRNA by sponging miR-525-5p to de-repress HO-1, thereby reducing ROS and inhibiting NF-kappaB activation, protecting ECM (Collagen II/Aggrecan) and promoting chondrocyte proliferation; its overexpression alleviates OA in an ACLT rabbit model. |
| Confidence score: |
0.8679 |